As a control, we first treated the glioma spheroids with an LMP‐inducing agent, L‐leucine O‐methyl (LLOMe; Uchimoto et al, 1999), which caused increased formation of galectin‐1 (LGALS1)‐positive puncta (Fig 4C and D). This evidence concerns the gene LGALS1 and central nervous system cancer.